| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Cytoplasmic and Nuclear | 24 | 2006 | 871 | 2.870 |
Why?
|
| Diabetic Angiopathies | 14 | 2019 | 820 | 2.180 |
Why?
|
| Arteriosclerosis | 20 | 2004 | 1092 | 2.160 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 8 | 2011 | 65 | 2.120 |
Why?
|
| Thiazolidinediones | 17 | 2014 | 476 | 1.970 |
Why?
|
| PPAR gamma | 10 | 2014 | 493 | 1.910 |
Why?
|
| PPAR alpha | 11 | 2019 | 196 | 1.900 |
Why?
|
| Transcription Factors | 34 | 2023 | 12207 | 1.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 33 | 2024 | 11732 | 1.670 |
Why?
|
| Muscle, Smooth, Vascular | 7 | 2019 | 1504 | 1.640 |
Why?
|
| Atherosclerosis | 22 | 2024 | 3444 | 1.530 |
Why?
|
| Cardiovascular Diseases | 45 | 2024 | 15161 | 1.480 |
Why?
|
| Retinoids | 4 | 2019 | 101 | 1.400 |
Why?
|
| Aldehyde Dehydrogenase | 3 | 2014 | 142 | 1.310 |
Why?
|
| Endothelium, Vascular | 21 | 2015 | 4455 | 1.090 |
Why?
|
| Hypoglycemic Agents | 16 | 2023 | 2875 | 1.060 |
Why?
|
| Inflammation | 24 | 2022 | 10634 | 1.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 21 | 2023 | 3256 | 1.020 |
Why?
|
| Retinoid X Receptors | 3 | 2011 | 93 | 1.000 |
Why?
|
| Lipase | 3 | 2013 | 315 | 0.960 |
Why?
|
| Transcription, Genetic | 16 | 2020 | 7723 | 0.920 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2019 | 232 | 0.860 |
Why?
|
| Hypolipidemic Agents | 11 | 2023 | 604 | 0.850 |
Why?
|
| Fatty Acids | 15 | 2023 | 1808 | 0.830 |
Why?
|
| Aorta | 4 | 2022 | 2061 | 0.780 |
Why?
|
| Coronary Artery Disease | 14 | 2023 | 6489 | 0.770 |
Why?
|
| Retinal Dehydrogenase | 4 | 2014 | 74 | 0.770 |
Why?
|
| Lipid Metabolism | 11 | 2020 | 1888 | 0.760 |
Why?
|
| Cholesterol | 10 | 2021 | 2911 | 0.740 |
Why?
|
| Dyslipidemias | 9 | 2019 | 849 | 0.730 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2019 | 30 | 0.730 |
Why?
|
| Lipoproteins, HDL | 3 | 2013 | 638 | 0.730 |
Why?
|
| Lipids | 7 | 2019 | 3305 | 0.660 |
Why?
|
| Triglycerides | 12 | 2021 | 2453 | 0.650 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 3646 | 0.640 |
Why?
|
| Transcription Factor RelA | 3 | 2015 | 275 | 0.610 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 8 | 2015 | 707 | 0.610 |
Why?
|
| Retinal Diseases | 1 | 2023 | 683 | 0.600 |
Why?
|
| Cholesterol, LDL | 13 | 2023 | 2355 | 0.590 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2020 | 635 | 0.550 |
Why?
|
| Diabetes Complications | 5 | 2019 | 1361 | 0.550 |
Why?
|
| Adipose Tissue | 7 | 2020 | 3278 | 0.550 |
Why?
|
| PPAR delta | 3 | 2013 | 43 | 0.530 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2019 | 687 | 0.520 |
Why?
|
| Lipoproteins, VLDL | 3 | 2011 | 201 | 0.510 |
Why?
|
| Adipose Tissue, White | 3 | 2020 | 346 | 0.500 |
Why?
|
| Osteogenesis | 2 | 2019 | 1299 | 0.500 |
Why?
|
| Lipoprotein Lipase | 6 | 2011 | 126 | 0.500 |
Why?
|
| Insulin Resistance | 11 | 2012 | 3863 | 0.490 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 107 | 0.490 |
Why?
|
| Nuclear Proteins | 6 | 2023 | 5853 | 0.480 |
Why?
|
| Monocytes | 6 | 2014 | 2594 | 0.480 |
Why?
|
| Body Temperature Regulation | 3 | 2020 | 252 | 0.460 |
Why?
|
| Adipogenesis | 5 | 2018 | 359 | 0.460 |
Why?
|
| Thermogenesis | 2 | 2020 | 429 | 0.460 |
Why?
|
| Diabetes Mellitus | 13 | 2024 | 5755 | 0.460 |
Why?
|
| Endothelium | 2 | 2022 | 778 | 0.440 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2020 | 340 | 0.440 |
Why?
|
| Hypobetalipoproteinemias | 1 | 2012 | 11 | 0.430 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2024 | 2208 | 0.410 |
Why?
|
| Histones | 2 | 2020 | 2600 | 0.410 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 1072 | 0.410 |
Why?
|
| Chemotaxis | 4 | 2024 | 607 | 0.400 |
Why?
|
| Animals | 62 | 2024 | 168788 | 0.400 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2013 | 350 | 0.400 |
Why?
|
| Humans | 153 | 2024 | 744220 | 0.400 |
Why?
|
| Systole | 1 | 2014 | 957 | 0.400 |
Why?
|
| Mice | 42 | 2024 | 81178 | 0.390 |
Why?
|
| Cholesterol, HDL | 4 | 2020 | 1814 | 0.390 |
Why?
|
| Gluconeogenesis | 1 | 2012 | 183 | 0.390 |
Why?
|
| Fenofibrate | 3 | 2007 | 88 | 0.390 |
Why?
|
| Sphingosine | 1 | 2013 | 307 | 0.380 |
Why?
|
| Glucose | 5 | 2018 | 4396 | 0.380 |
Why?
|
| Lysophospholipids | 1 | 2013 | 331 | 0.380 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2010 | 8 | 0.370 |
Why?
|
| Myocardial Infarction | 12 | 2023 | 11728 | 0.370 |
Why?
|
| Cells, Cultured | 18 | 2019 | 19227 | 0.360 |
Why?
|
| Mice, Knockout | 17 | 2024 | 14556 | 0.350 |
Why?
|
| Liver | 7 | 2013 | 7472 | 0.350 |
Why?
|
| Aortic Valve | 1 | 2019 | 1921 | 0.350 |
Why?
|
| Incretins | 1 | 2010 | 88 | 0.350 |
Why?
|
| Energy Metabolism | 3 | 2020 | 2895 | 0.350 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2022 | 3712 | 0.350 |
Why?
|
| Gene Expression Regulation | 15 | 2020 | 12075 | 0.340 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2014 | 4419 | 0.340 |
Why?
|
| Hypercholesterolemia | 4 | 2023 | 1151 | 0.330 |
Why?
|
| Clinical Medicine | 1 | 2010 | 147 | 0.320 |
Why?
|
| Quinazolinones | 2 | 2020 | 221 | 0.320 |
Why?
|
| Signal Transduction | 14 | 2023 | 23404 | 0.320 |
Why?
|
| Retinaldehyde | 1 | 2007 | 25 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 18 | 2024 | 21824 | 0.310 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2011 | 293 | 0.300 |
Why?
|
| Tibia | 1 | 2013 | 1077 | 0.300 |
Why?
|
| Isoenzymes | 1 | 2012 | 1726 | 0.300 |
Why?
|
| Prediabetic State | 3 | 2013 | 499 | 0.300 |
Why?
|
| Lipolysis | 5 | 2007 | 210 | 0.290 |
Why?
|
| Femur | 1 | 2013 | 1297 | 0.290 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 4742 | 0.290 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2023 | 1121 | 0.290 |
Why?
|
| Acute Coronary Syndrome | 1 | 2020 | 2337 | 0.280 |
Why?
|
| Hyperglycemia | 4 | 2014 | 1372 | 0.280 |
Why?
|
| Lipoproteins | 4 | 2023 | 878 | 0.280 |
Why?
|
| Hypertension | 5 | 2023 | 8480 | 0.280 |
Why?
|
| Lipoproteins, LDL | 4 | 2004 | 639 | 0.270 |
Why?
|
| Growth Inhibitors | 1 | 2007 | 385 | 0.270 |
Why?
|
| Azepines | 3 | 2020 | 336 | 0.270 |
Why?
|
| Obesity | 12 | 2023 | 12742 | 0.270 |
Why?
|
| Peripheral Arterial Disease | 3 | 2023 | 1188 | 0.260 |
Why?
|
| Vascular Diseases | 2 | 2011 | 1161 | 0.260 |
Why?
|
| Overweight | 5 | 2023 | 2370 | 0.260 |
Why?
|
| Leukocytes | 4 | 2007 | 2040 | 0.260 |
Why?
|
| beta Carotene | 1 | 2006 | 527 | 0.250 |
Why?
|
| Peroxisome Proliferators | 2 | 2002 | 8 | 0.250 |
Why?
|
| Carotid Arteries | 5 | 2020 | 952 | 0.250 |
Why?
|
| Acetylation | 2 | 2020 | 1085 | 0.250 |
Why?
|
| Ligands | 8 | 2012 | 3294 | 0.250 |
Why?
|
| Physician's Role | 1 | 2011 | 942 | 0.240 |
Why?
|
| Tretinoin | 2 | 2019 | 517 | 0.240 |
Why?
|
| Coronary Vessels | 4 | 2021 | 3107 | 0.230 |
Why?
|
| Coronary Disease | 6 | 2006 | 6078 | 0.230 |
Why?
|
| Macrophages | 6 | 2024 | 5657 | 0.230 |
Why?
|
| Alkaline Phosphatase | 2 | 2019 | 865 | 0.230 |
Why?
|
| Glucagon-Like Peptides | 2 | 2023 | 127 | 0.230 |
Why?
|
| Adipocytes | 5 | 2020 | 1182 | 0.230 |
Why?
|
| Cell Adhesion | 5 | 2014 | 3144 | 0.220 |
Why?
|
| Porphyrias, Hepatic | 1 | 2022 | 7 | 0.220 |
Why?
|
| Eligibility Determination | 2 | 2017 | 403 | 0.220 |
Why?
|
| RNA Polymerase II | 3 | 2016 | 551 | 0.220 |
Why?
|
| Thiazoles | 5 | 2002 | 1484 | 0.220 |
Why?
|
| Prostaglandin D2 | 5 | 2008 | 122 | 0.210 |
Why?
|
| Triazoles | 3 | 2020 | 911 | 0.210 |
Why?
|
| Hyperhomocysteinemia | 1 | 2022 | 124 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatases | 3 | 1992 | 473 | 0.200 |
Why?
|
| Endothelial Cells | 6 | 2023 | 3478 | 0.200 |
Why?
|
| Dietary Fats | 2 | 2010 | 2017 | 0.200 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 2001 | 9 | 0.200 |
Why?
|
| Biology | 1 | 2023 | 294 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2004 | 1789 | 0.200 |
Why?
|
| Collagenases | 2 | 1998 | 228 | 0.190 |
Why?
|
| Anticholesteremic Agents | 4 | 2020 | 979 | 0.190 |
Why?
|
| Receptors, sigma | 1 | 2020 | 28 | 0.190 |
Why?
|
| Simvastatin | 2 | 2001 | 360 | 0.190 |
Why?
|
| Retinol-Binding Proteins | 1 | 2020 | 65 | 0.190 |
Why?
|
| MicroRNAs | 3 | 2023 | 3747 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 4752 | 0.190 |
Why?
|
| Dicarboxylic Acids | 1 | 2020 | 70 | 0.190 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 985 | 0.190 |
Why?
|
| Mice, Obese | 3 | 2011 | 424 | 0.190 |
Why?
|
| Antirheumatic Agents | 2 | 2022 | 1339 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2014 | 4289 | 0.180 |
Why?
|
| Bone Density | 1 | 2013 | 3468 | 0.180 |
Why?
|
| Apolipoprotein C-III | 2 | 2019 | 202 | 0.180 |
Why?
|
| Cardiology | 1 | 2011 | 1668 | 0.180 |
Why?
|
| Diabetic Foot | 1 | 2023 | 355 | 0.180 |
Why?
|
| Hypertriglyceridemia | 3 | 2011 | 293 | 0.180 |
Why?
|
| Risk Factors | 24 | 2024 | 72280 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2023 | 8551 | 0.180 |
Why?
|
| Hydrolysis | 3 | 2011 | 682 | 0.170 |
Why?
|
| Oxidative Stress | 4 | 2010 | 3085 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 4385 | 0.170 |
Why?
|
| Isotretinoin | 1 | 2019 | 114 | 0.170 |
Why?
|
| Thromboplastin | 1 | 2001 | 291 | 0.170 |
Why?
|
| Drug Tolerance | 1 | 2020 | 376 | 0.170 |
Why?
|
| Pravastatin | 1 | 2001 | 395 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2019 | 77 | 0.160 |
Why?
|
| Neovascularization, Physiologic | 3 | 2023 | 1351 | 0.160 |
Why?
|
| Butyrates | 1 | 2019 | 163 | 0.160 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 1341 | 0.160 |
Why?
|
| Neointima | 1 | 2019 | 135 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 2636 | 0.160 |
Why?
|
| Male | 46 | 2023 | 350027 | 0.160 |
Why?
|
| Cell Transdifferentiation | 1 | 2019 | 171 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 840 | 0.160 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1999 | 281 | 0.150 |
Why?
|
| Aortic Diseases | 1 | 2024 | 742 | 0.150 |
Why?
|
| Female | 42 | 2023 | 380197 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 9960 | 0.150 |
Why?
|
| Vascular Grafting | 1 | 2019 | 142 | 0.150 |
Why?
|
| NF-kappa B | 7 | 2016 | 2501 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 850 | 0.150 |
Why?
|
| Angina, Unstable | 1 | 2001 | 926 | 0.150 |
Why?
|
| Chromans | 4 | 2002 | 122 | 0.150 |
Why?
|
| Cardiovascular System | 2 | 2021 | 832 | 0.150 |
Why?
|
| Adiposity | 3 | 2014 | 1807 | 0.150 |
Why?
|
| Arrestins | 1 | 2017 | 74 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 10949 | 0.140 |
Why?
|
| HIV Infections | 4 | 2021 | 16718 | 0.140 |
Why?
|
| 3T3-L1 Cells | 2 | 2007 | 197 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 1955 | 0.140 |
Why?
|
| Metalloproteases | 1 | 2016 | 62 | 0.140 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 3461 | 0.140 |
Why?
|
| Interferon-gamma | 2 | 2002 | 3203 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2017 | 246 | 0.140 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2019 | 373 | 0.140 |
Why?
|
| Troponin T | 1 | 2021 | 753 | 0.140 |
Why?
|
| Transfection | 6 | 2020 | 5892 | 0.140 |
Why?
|
| Mesoderm | 1 | 2019 | 686 | 0.140 |
Why?
|
| RNA, Messenger | 14 | 2016 | 13036 | 0.130 |
Why?
|
| Adiponectin | 3 | 2018 | 1100 | 0.130 |
Why?
|
| Fasting | 2 | 2020 | 1591 | 0.130 |
Why?
|
| E-Selectin | 2 | 2015 | 579 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 2279 | 0.130 |
Why?
|
| Heart Failure | 5 | 2023 | 10905 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 849 | 0.130 |
Why?
|
| Pyrimidines | 4 | 2002 | 2940 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 2538 | 0.130 |
Why?
|
| Risk Assessment | 12 | 2024 | 23337 | 0.130 |
Why?
|
| SOXF Transcription Factors | 1 | 2014 | 29 | 0.130 |
Why?
|
| Protein Isoforms | 3 | 2012 | 1731 | 0.130 |
Why?
|
| Orphan Nuclear Receptors | 2 | 2006 | 60 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 1080 | 0.120 |
Why?
|
| DNA-Binding Proteins | 4 | 2006 | 9647 | 0.120 |
Why?
|
| Lipoprotein(a) | 3 | 2024 | 435 | 0.120 |
Why?
|
| Gene Expression | 6 | 2011 | 7799 | 0.120 |
Why?
|
| Blood Vessels | 1 | 2000 | 1126 | 0.120 |
Why?
|
| Middle Aged | 28 | 2023 | 213367 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2016 | 224 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2010 | 3311 | 0.120 |
Why?
|
| Double-Blind Method | 6 | 2023 | 12035 | 0.120 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 249 | 0.120 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2024 | 1519 | 0.120 |
Why?
|
| Cell Movement | 3 | 2014 | 5216 | 0.120 |
Why?
|
| Glucosides | 1 | 2018 | 451 | 0.120 |
Why?
|
| Response Elements | 1 | 2015 | 311 | 0.120 |
Why?
|
| Stroke | 5 | 2023 | 9981 | 0.120 |
Why?
|
| RNA, Small Interfering | 3 | 2023 | 3505 | 0.120 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 645 | 0.110 |
Why?
|
| Fatty Liver | 2 | 2011 | 729 | 0.110 |
Why?
|
| Registries | 5 | 2021 | 8090 | 0.110 |
Why?
|
| Alkanesulfonates | 1 | 2012 | 15 | 0.110 |
Why?
|
| Phosphorylation | 3 | 2013 | 8437 | 0.110 |
Why?
|
| Phenylpropionates | 1 | 2012 | 30 | 0.110 |
Why?
|
| Tunica Intima | 1 | 2015 | 464 | 0.110 |
Why?
|
| Smad Proteins | 1 | 2013 | 162 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 1573 | 0.110 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2013 | 164 | 0.110 |
Why?
|
| Apolipoprotein A-I | 2 | 2021 | 281 | 0.110 |
Why?
|
| Hepatocytes | 2 | 2012 | 1210 | 0.110 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 204 | 0.110 |
Why?
|
| American Heart Association | 3 | 2023 | 1056 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 5 | 2015 | 5867 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3506 | 0.110 |
Why?
|
| Blotting, Northern | 3 | 2003 | 1581 | 0.110 |
Why?
|
| Calorimetry | 1 | 2012 | 126 | 0.110 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2013 | 122 | 0.110 |
Why?
|
| Sodium | 1 | 2018 | 1623 | 0.110 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 428 | 0.100 |
Why?
|
| Carrier Proteins | 2 | 2019 | 5021 | 0.100 |
Why?
|
| Insulin | 3 | 2014 | 6583 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 7281 | 0.100 |
Why?
|
| Intermittent Claudication | 1 | 2014 | 309 | 0.100 |
Why?
|
| Lipogenesis | 1 | 2013 | 212 | 0.100 |
Why?
|
| Cattle | 5 | 2010 | 3922 | 0.100 |
Why?
|
| Oxygen | 1 | 2023 | 4187 | 0.100 |
Why?
|
| Stem Cell Factor | 1 | 2012 | 219 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 845 | 0.100 |
Why?
|
| Adipose Tissue, Brown | 2 | 2020 | 754 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 2148 | 0.100 |
Why?
|
| Oxazoles | 1 | 2012 | 189 | 0.100 |
Why?
|
| Weight Loss | 2 | 2020 | 2622 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5523 | 0.100 |
Why?
|
| Oxazines | 1 | 2012 | 298 | 0.100 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 791 | 0.100 |
Why?
|
| Blotting, Western | 3 | 2012 | 5180 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1992 | 462 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2014 | 794 | 0.090 |
Why?
|
| Apolipoproteins B | 2 | 2023 | 374 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 689 | 0.090 |
Why?
|
| Anilides | 1 | 2013 | 405 | 0.090 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 300 | 0.090 |
Why?
|
| Rural Population | 1 | 2020 | 2210 | 0.090 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 882 | 0.090 |
Why?
|
| Mice, Transgenic | 4 | 2012 | 9735 | 0.090 |
Why?
|
| Osteopontin | 1 | 2011 | 296 | 0.090 |
Why?
|
| Reactive Oxygen Species | 2 | 2009 | 2078 | 0.090 |
Why?
|
| COS Cells | 1 | 2011 | 1161 | 0.080 |
Why?
|
| Oxidation-Reduction | 3 | 2023 | 2187 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 658 | 0.080 |
Why?
|
| Glycine | 1 | 2012 | 671 | 0.080 |
Why?
|
| Saphenous Vein | 4 | 2000 | 532 | 0.080 |
Why?
|
| Diet | 1 | 2007 | 7937 | 0.080 |
Why?
|
| Catalytic Domain | 1 | 2011 | 698 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2010 | 638 | 0.080 |
Why?
|
| Nitric Oxide Synthase | 2 | 2004 | 916 | 0.080 |
Why?
|
| Protein Binding | 2 | 2014 | 9392 | 0.080 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 514 | 0.080 |
Why?
|
| Amino Acids | 1 | 2015 | 1734 | 0.080 |
Why?
|
| Thioredoxins | 1 | 2010 | 213 | 0.080 |
Why?
|
| Osteoblasts | 1 | 2014 | 1165 | 0.080 |
Why?
|
| Skin | 1 | 2022 | 4363 | 0.080 |
Why?
|
| Flavonoids | 1 | 2011 | 443 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5096 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2020 | 3690 | 0.080 |
Why?
|
| Endothelins | 1 | 2008 | 138 | 0.080 |
Why?
|
| Apolipoproteins A | 2 | 2023 | 94 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 1725 | 0.080 |
Why?
|
| Leukotriene E4 | 1 | 2008 | 79 | 0.080 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 469 | 0.080 |
Why?
|
| Disease Progression | 3 | 2011 | 13280 | 0.080 |
Why?
|
| Treatment Outcome | 12 | 2020 | 63119 | 0.080 |
Why?
|
| Myocardial Revascularization | 2 | 2023 | 841 | 0.080 |
Why?
|
| Myocardium | 1 | 2021 | 4776 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2021 | 2790 | 0.080 |
Why?
|
| Thiophenes | 1 | 2012 | 589 | 0.080 |
Why?
|
| Receptors, LDL | 2 | 2024 | 475 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 3508 | 0.080 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 7908 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4201 | 0.080 |
Why?
|
| Adult | 19 | 2023 | 214035 | 0.080 |
Why?
|
| Aged | 19 | 2023 | 163253 | 0.070 |
Why?
|
| Ion Channels | 1 | 2012 | 1056 | 0.070 |
Why?
|
| Walking | 1 | 2014 | 1180 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 15070 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2016 | 1186 | 0.070 |
Why?
|
| Cytokines | 3 | 2007 | 7326 | 0.070 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2006 | 9 | 0.070 |
Why?
|
| Genes | 2 | 1992 | 1893 | 0.070 |
Why?
|
| United States | 11 | 2023 | 69867 | 0.070 |
Why?
|
| Aryldialkylphosphatase | 1 | 2006 | 63 | 0.070 |
Why?
|
| Angiotensin II | 2 | 2022 | 881 | 0.070 |
Why?
|
| Serum Amyloid A Protein | 1 | 2006 | 121 | 0.070 |
Why?
|
| Pericytes | 1 | 2009 | 291 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 996 | 0.070 |
Why?
|
| RNA Interference | 2 | 2012 | 2890 | 0.070 |
Why?
|
| Chromatin | 2 | 2014 | 2934 | 0.070 |
Why?
|
| Retrospective Studies | 13 | 2024 | 77426 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 1869 | 0.070 |
Why?
|
| Heart Transplantation | 2 | 2013 | 3123 | 0.070 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 677 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 1889 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 2014 | 0.060 |
Why?
|
| Rats | 5 | 2019 | 24273 | 0.060 |
Why?
|
| Podocytes | 1 | 2009 | 396 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 1613 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2023 | 12718 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1583 | 0.060 |
Why?
|
| Uganda | 2 | 2020 | 1243 | 0.060 |
Why?
|
| Homeostasis | 2 | 2013 | 3339 | 0.060 |
Why?
|
| Microvessels | 1 | 2009 | 544 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2503 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2011 | 1598 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 626 | 0.060 |
Why?
|
| Learning | 1 | 2014 | 1713 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 3846 | 0.060 |
Why?
|
| Ischemia | 2 | 2023 | 1914 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2047 | 0.060 |
Why?
|
| Linoleic Acids | 1 | 2003 | 38 | 0.060 |
Why?
|
| Blood Glucose | 4 | 2014 | 6259 | 0.060 |
Why?
|
| Primary Prevention | 2 | 2012 | 1167 | 0.060 |
Why?
|
| Apoprotein(a) | 1 | 2023 | 18 | 0.060 |
Why?
|
| Foam Cells | 1 | 2003 | 71 | 0.060 |
Why?
|
| Incidence | 6 | 2020 | 20945 | 0.060 |
Why?
|
| Electrochemistry | 1 | 2003 | 145 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 546 | 0.060 |
Why?
|
| Vitamin A | 2 | 2020 | 615 | 0.060 |
Why?
|
| Viral Load | 1 | 2012 | 3300 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2003 | 193 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 534 | 0.060 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2022 | 27 | 0.060 |
Why?
|
| Patient Selection | 1 | 2015 | 4216 | 0.050 |
Why?
|
| Inhibins | 1 | 2023 | 211 | 0.050 |
Why?
|
| Cholesterol, Dietary | 2 | 2015 | 231 | 0.050 |
Why?
|
| Pyridoxine | 1 | 2022 | 103 | 0.050 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2022 | 29 | 0.050 |
Why?
|
| Diabetic Retinopathy | 1 | 2011 | 1210 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2012 | 2924 | 0.050 |
Why?
|
| Radiography | 1 | 2013 | 7022 | 0.050 |
Why?
|
| Interleukin-9 | 1 | 2022 | 63 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2010 | 2751 | 0.050 |
Why?
|
| Sulfur | 1 | 2022 | 166 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 15538 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 2624 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 1125 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3760 | 0.050 |
Why?
|
| Cell Line | 2 | 2011 | 15999 | 0.050 |
Why?
|
| Pharmacists | 1 | 2024 | 247 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2021 | 3201 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 57768 | 0.050 |
Why?
|
| Gemfibrozil | 1 | 2001 | 30 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2001 | 71 | 0.050 |
Why?
|
| Vitamin B 6 | 1 | 2022 | 237 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 9275 | 0.050 |
Why?
|
| Withholding Treatment | 2 | 2017 | 599 | 0.050 |
Why?
|
| Glycoproteins | 2 | 1986 | 2263 | 0.050 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2020 | 52 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 1772 | 0.050 |
Why?
|
| Rabbits | 1 | 2007 | 4892 | 0.050 |
Why?
|
| Mast Cells | 1 | 2008 | 1544 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2010 | 2700 | 0.050 |
Why?
|
| Heme | 1 | 2022 | 307 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2008 | 3701 | 0.050 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2020 | 137 | 0.050 |
Why?
|
| Hyperlipidemias | 2 | 2002 | 788 | 0.050 |
Why?
|
| Glucose Clamp Technique | 2 | 2011 | 266 | 0.050 |
Why?
|
| Spironolactone | 1 | 2023 | 382 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2003 | 592 | 0.040 |
Why?
|
| Methionine | 1 | 2022 | 590 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2004 | 2007 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2020 | 386 | 0.040 |
Why?
|
| Anisotropy | 1 | 2023 | 1265 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2013 | 10480 | 0.040 |
Why?
|
| Androstenes | 1 | 2020 | 169 | 0.040 |
Why?
|
| C-Reactive Protein | 2 | 2021 | 3778 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2019 | 71 | 0.040 |
Why?
|
| Phospholipids | 1 | 2023 | 781 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2011 | 7879 | 0.040 |
Why?
|
| RNA | 2 | 2022 | 2749 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 504 | 0.040 |
Why?
|
| Homocysteine | 1 | 2022 | 647 | 0.040 |
Why?
|
| U937 Cells | 1 | 1999 | 268 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2005 | 1573 | 0.040 |
Why?
|
| Young Adult | 6 | 2023 | 56436 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 357 | 0.040 |
Why?
|
| Models, Biological | 3 | 2008 | 9582 | 0.040 |
Why?
|
| Necrosis | 1 | 2023 | 1643 | 0.040 |
Why?
|
| Vasomotor System | 1 | 1999 | 209 | 0.040 |
Why?
|
| Fish Oils | 1 | 2002 | 470 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 1999 | 354 | 0.040 |
Why?
|
| Dinoprost | 1 | 1998 | 138 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 422 | 0.040 |
Why?
|
| Cohort Studies | 6 | 2019 | 40559 | 0.040 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 5319 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2013 | 4463 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 552 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 1792 | 0.040 |
Why?
|
| Mortality | 2 | 2021 | 2864 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2007 | 3741 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 1998 | 251 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 1240 | 0.040 |
Why?
|
| Muscles | 2 | 2013 | 1622 | 0.040 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2020 | 302 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 924 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2006 | 2969 | 0.040 |
Why?
|
| Software | 1 | 2011 | 4442 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 821 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 535 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 15226 | 0.040 |
Why?
|
| Gelatin | 1 | 1998 | 225 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 16687 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2020 | 4217 | 0.040 |
Why?
|
| DNA | 4 | 2001 | 7303 | 0.040 |
Why?
|
| Luciferases | 1 | 1999 | 733 | 0.040 |
Why?
|
| Transplants | 1 | 2019 | 209 | 0.040 |
Why?
|
| Base Sequence | 5 | 1992 | 12801 | 0.040 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 2216 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1518 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12244 | 0.040 |
Why?
|
| Mass Screening | 1 | 2012 | 5252 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 1423 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 1990 | 3842 | 0.030 |
Why?
|
| Blood Coagulation | 2 | 1999 | 1127 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 625 | 0.030 |
Why?
|
| Recurrence | 1 | 2008 | 8343 | 0.030 |
Why?
|
| Folic Acid | 1 | 2022 | 1300 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2021 | 853 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2019 | 476 | 0.030 |
Why?
|
| Cloning, Molecular | 3 | 1992 | 4321 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 25043 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 8661 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 2008 | 0.030 |
Why?
|
| Syndrome | 1 | 2001 | 3250 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2029 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2023 | 3913 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 1836 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2002 | 1904 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 1799 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1999 | 1547 | 0.030 |
Why?
|
| Carotid Artery Injuries | 1 | 2015 | 96 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2019 | 764 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3270 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 11368 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1184 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1655 | 0.030 |
Why?
|
| Natural Language Processing | 2 | 2013 | 1040 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 2867 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2022 | 2480 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 78 | 0.030 |
Why?
|
| Algorithms | 3 | 2020 | 13885 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 950 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 1438 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5442 | 0.030 |
Why?
|
| Aftercare | 1 | 2019 | 866 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2023 | 5076 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 539 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2016 | 9849 | 0.030 |
Why?
|
| Disease Management | 1 | 2024 | 2458 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1350 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 3611 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2002 | 1344 | 0.030 |
Why?
|
| Risk | 3 | 2012 | 9685 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2019 | 1531 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2000 | 1676 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1992 | 1375 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1992 | 13817 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3769 | 0.030 |
Why?
|
| Hybrid Cells | 1 | 1992 | 441 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 4328 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 675 | 0.030 |
Why?
|
| Vaccinium macrocarpon | 1 | 2011 | 12 | 0.030 |
Why?
|
| Physicians | 1 | 1990 | 4564 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 2013 | 411 | 0.030 |
Why?
|
| Apolipoprotein C-II | 1 | 2011 | 10 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 6612 | 0.030 |
Why?
|
| Receptors, Adiponectin | 1 | 2011 | 81 | 0.020 |
Why?
|
| Graft Survival | 1 | 2002 | 3740 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1992 | 803 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 627 | 0.020 |
Why?
|
| Age Factors | 2 | 2019 | 18367 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 4553 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 1992 | 297 | 0.020 |
Why?
|
| Cause of Death | 1 | 2021 | 3584 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 314 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2011 | 218 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1992 | 18116 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 1992 | 2256 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1999 | 2131 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 940 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 2013 | 620 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2020 | 21752 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 2958 | 0.020 |
Why?
|
| Systems Integration | 1 | 2011 | 440 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2019 | 1859 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2014 | 770 | 0.020 |
Why?
|
| Mutation | 2 | 2011 | 29784 | 0.020 |
Why?
|
| Apolipoproteins | 1 | 2011 | 316 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2021 | 2494 | 0.020 |
Why?
|
| Protein C | 2 | 1986 | 138 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 905 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 1741 | 0.020 |
Why?
|
| Health | 1 | 2011 | 394 | 0.020 |
Why?
|
| Calcium | 1 | 2021 | 5757 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 3509 | 0.020 |
Why?
|
| Leukotriene D4 | 1 | 2008 | 38 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2010 | 1101 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1999 | 4156 | 0.020 |
Why?
|
| Tyrosine | 1 | 1992 | 1461 | 0.020 |
Why?
|
| Kidney | 1 | 2024 | 7183 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2011 | 608 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 1682 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2020 | 5008 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2727 | 0.020 |
Why?
|
| Body Composition | 1 | 2017 | 2400 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 7784 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 834 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 35423 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2002 | 582 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 5982 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2010 | 676 | 0.020 |
Why?
|
| Comorbidity | 1 | 2021 | 10387 | 0.020 |
Why?
|
| Documentation | 1 | 2013 | 869 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 415 | 0.020 |
Why?
|
| Thiocarbamates | 1 | 2006 | 31 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 12355 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 2075 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3528 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 1990 | 535 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 2252 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2011 | 591 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 18027 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 3923 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2006 | 225 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 2120 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 625 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1985 | 170 | 0.020 |
Why?
|
| Time Factors | 2 | 2019 | 40063 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 4259 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 1438 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 1637 | 0.020 |
Why?
|
| Proline | 1 | 2006 | 458 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3800 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 3001 | 0.010 |
Why?
|
| Microcirculation | 1 | 2008 | 1286 | 0.010 |
Why?
|
| Chemokines | 1 | 2008 | 969 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 2872 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2015 | 4578 | 0.010 |
Why?
|
| Fluoroimmunoassay | 1 | 2002 | 33 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 4776 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 10182 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 6172 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1986 | 772 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 937 | 0.010 |
Why?
|
| Sex Factors | 1 | 2016 | 10396 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5138 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2277 | 0.010 |
Why?
|
| Cell Survival | 1 | 2012 | 5881 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2002 | 433 | 0.010 |
Why?
|
| Collagen | 1 | 2010 | 2689 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2018 | 4556 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 996 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 611 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1985 | 1154 | 0.010 |
Why?
|
| Chemokine CXCL11 | 1 | 2000 | 42 | 0.010 |
Why?
|
| Microbodies | 1 | 2000 | 36 | 0.010 |
Why?
|
| Body Weight | 1 | 2011 | 4666 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11478 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1986 | 1073 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2013 | 4399 | 0.010 |
Why?
|
| Chemokine CXCL9 | 1 | 2000 | 132 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2021 | 53280 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 825 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2000 | 370 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13409 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1986 | 1076 | 0.010 |
Why?
|
| Heart | 1 | 2013 | 4465 | 0.010 |
Why?
|
| Leukemia | 1 | 2008 | 1508 | 0.010 |
Why?
|
| Smoking | 1 | 2016 | 8986 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2000 | 237 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2000 | 304 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12781 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29050 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 2957 | 0.010 |
Why?
|
| Mevalonic Acid | 1 | 1998 | 42 | 0.010 |
Why?
|
| Lovastatin | 1 | 1998 | 120 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 6116 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 39045 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2000 | 669 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8628 | 0.010 |
Why?
|
| Health Promotion | 1 | 2008 | 2205 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14726 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 9728 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 2147 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 4407 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2000 | 875 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 1213 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 3494 | 0.010 |
Why?
|
| Metformin | 1 | 1999 | 835 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1992 | 377 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1992 | 457 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8321 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 6938 | 0.010 |
Why?
|
| Antioxidants | 1 | 1999 | 1663 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 708 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2003 | 2958 | 0.010 |
Why?
|
| Neutrophils | 1 | 2002 | 3717 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 6274 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 12956 | 0.000 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1992 | 2839 | 0.000 |
Why?
|
| Deoxyribonuclease BamHI | 1 | 1985 | 17 | 0.000 |
Why?
|
| Factor X | 1 | 1985 | 64 | 0.000 |
Why?
|
| Factor IX | 1 | 1985 | 77 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1985 | 570 | 0.000 |
Why?
|
| Prothrombin | 1 | 1985 | 185 | 0.000 |
Why?
|
| Child | 1 | 2012 | 77679 | 0.000 |
Why?
|
| Adolescent | 1 | 2011 | 85759 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 17449 | 0.000 |
Why?
|
| Brain | 1 | 1992 | 26413 | 0.000 |
Why?
|